<DOC>
	<DOCNO>NCT02083653</DOCNO>
	<brief_summary>This Phase 2 , open-label , 3-arm trial two Sym004 dos ( Arms A B ) control group ( Arm C ) subject metastatic colorectal cancer ( mCRC ) acquire resistance anti-epidermal growth factor receptor ( EGFR ) monoclonal antibody ( mAbs ) .</brief_summary>
	<brief_title>Sym004 vs Standard Care Subjects With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Written inform consent obtain undergoing studyrelated activity Male female , least 18 year age Subjects histologically cytologically confirm mCRC , Kirsten rat sarcoma wildtype ( KRAS WT ) initial diagnosis Failure intolerance 5FU , Oxaliplatin , Irinotecan Acquired resistance market antiEGFR mAbs define protocol Measurable disease define one target lesion accord RECIST Life expectancy least 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 1 Other protocol define inclusion criterion could apply Pretreatment regorafenib . Subjects opinion subject investigator would benefit regorafenib treatment ( except regorafenib reimbursed country ) Skin rash Common Terminology Criteria AEs ( CTCAE ) Grade great 1 previous antiEGFR therapy time randomization Magnesium le 0.9 milligram per deciliter ( mg/dL ) Known hypersensitivity treatment ingredient . Known previous Grade 34 infusion relate reaction antiEGFR mABs Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Sym004</keyword>
	<keyword>Best Supportive Care</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Fluorouracil ( 5-FU )</keyword>
</DOC>